Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

23

May 2019

Be The Match BioTherapies® Announces Strategic Collaboration with Kiadis Pharma to Accelerate Patient Access to Haploidentical Stem Cell Therapies

Be The Match BioTherapies an organization offering solutions for companies developing and commercializing cell and gene therapies and Kiadis Pharma NV Kiadis Euronext Amsterdam and Brussels KDS a clinical stage biopharmaceutical company today announced a strategic collaboration to support clinical e...

23

May 2019

Halozyme Announces argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement

Halozyme Therapeutics Inc a biotechnology company developing novel oncology and drugdelivery therapies today announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February

22

May 2019

Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration

Gotham Therapeutics a biotechnology company developing a novel drug class targeting RNAmodifying proteins and ZoBio the leading contract research organization in integrated fragmentbased drug discovery today announced significant progress made as part of their collaboration to identify therapeutic l...

22

May 2019

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

Merck known as MSD outside the United States and Canada and Peloton Therapeutics Inc today announced that the companies have entered into a definitive agreement under which Merck through a subsidiary will acquire privately held Peloton a clinicalstage biopharmaceutical company

21

May 2019

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

Kazia Therapeutics Limited an Australian oncologyfocused biotechnology company is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation Alliance a USbased cancer research network sponsored by the National Cancer Institute

press releasesRead more...

23

May 2019

ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

ProBioGen AG a premier service and technology provider for complex therapeutic antibodies and glycoproteins today announced the closing of a services and license agreement with Abcuro Inc Pursuing a new generation of immune modulatory biotherapeutics Abcuro has developed a new first in class antibod...

23

May 2019

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

Agile Therapeutics Inc a womens healthcare company today announced that the US Food and Drug Administration FDA has accepted for review the Companys New Drug Application NDA resubmission for Twirla AG an investigational lowdose combined hormonal contraceptive patch

23

May 2019

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Therapeutics Inc has engaged Echelon Wealth Partners to determine the value on a riskadjusted basis of its cannabidiol CBD therapeutic products for the prevention and treatment of graft versus host disease GVHD and to assist with the review of potential outlicensing opportunities for the co...

22

May 2019

Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy

Avalon GloboCare Corp a leading global developer of cellbased technologies and therapeutics today announced it has entered into a sponsored research and licensing agreement with Massachusetts Institute of Technology MIT to generate novel therapeutic targets for cellular therapy using artificial inte...

22

May 2019

Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse

Santhera Pharmaceuticals announces its collaboration with the Biozentrum of the University of Basel to advance gene therapy research for the treatment of LAMAdeficient congenital muscular dystrophy LAMA MD or MDCA

EventsRead more...

23 - 24

May 2019

Hospital Management and Patient Safety 2019

Meetings International Pte Ltd
Las Vegas

28 - 28

May 2019

10th Annual Clinical Trials Summit 2019

Virtue Insight
Kohinoor Continental Hotel

28 - 30

May 2019

8th Annual Biologics Manufacturing Korea 2019

Imapac
Novotel Ambassador Seoul Gangnam

03 - 04

Jun 2019

Pre-Filled Syringes West Coast 2019


Hyatt Regency Mission Bay Spa and Marina

Advertisements

Rousselot - X-PURE®

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    Ligand Decorated Theranostic Nanomedicines

    The drug absorption in cancer cells from the conventional dosage form is limited due to poor dissolution toxic effect and drug resistance along with debilitating adverse effects such as nausea vomiting temporary loss of physical strength and energy neuropathy and finally organ failure

EDITORIAL SECTION